- 學位論文
抗高血壓治療可改善新診斷第2型糖尿病患者的血糖控制：一項前瞻性研究
Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study
摘要
背景：第2型糖尿病 (T2DM) 是一種慢性代謝性疾病，涉及進行性胰腺功能障礙。儘管進行了藥物治療，但仍有相當一部分 T2DM 患者無法達到血糖正常。之前的臨床研究表明，高血壓會導致葡萄糖失調，本研究中我們假設抗高血壓治療可能會改善 T2DM 患者的血糖控制。 研究方法：這項前瞻性隊列研究調查了在標準糖尿病治療中加入抗高血壓藥物amlodipine，對新診斷的 T2DM 患者血清糖化血色素 (HbA1c) 和脂質譜的影響。本研究共招募了 168 名新診斷為 T2DM 的參與者。 研究結果：我們的結果發現，使用抗高血壓藥物amlodipine的組別，在24週後標準糖尿病治療的組別相比表現出顯著較低的血清糖化血色素HbA1c （6.62% 對 7.01%，P = 0.01）、收縮壓（132 mmHg 對 143 mmHg，P < 0.001）和舒張壓（78.9 mmHg 對 86.0 mm Hg，P <0.001）。 結論：本研究的結論為 amlodipine抗高血壓治療改善了 T2DM 患者的血糖控制，可能是伴有高血壓的糖尿病患者的合適選擇，以幫助維持血糖正常。
並列摘要
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder involving progressive pancreatic dysfunction. A substantial proportion of patients with T2DM cannot achieve euglycemia despite pharmacological therapy. Previous clinical studies have shown that hypertension contributes to glucose dysregulation, and investigators in this study hypothesized that antihypertensive treatment may improve glycemic control in patients with T2DM. Methods: This prospective cohort study investigates the effect of adding the antihypertensive drug Amlodipine to standard diabetes therapy on serum glycosylated hemoglobin A1c (HbA1c) and lipid profile in patients with newly diagnosed T2DM. The study enrolled a total of 168 participants with newly diagnosed T2DM. Results: Recipients of an additional antihypertensive drug Amlodipine demonstrated significantly lower serum HbA1c (6.62% vs. 7.01%, P = 0.01), systolic blood pressure (132 mm Hg vs. 143 mm Hg, P < 0.001), and diastolic blood pressure (78.9 mm Hg vs. 86.0 mm Hg, P <0.001) compared to recipients of standard diabetes therapy after 24 weeks. Conclusions: Antihypertensive treatment with Amlodipine in addition to standard diabetes therapy improves glycemic control in patients with T2DM and may be an appropriate option in people with diabetes and concomitant hypertension to help maintain euglycemia.